Quantcast
Last updated on April 20, 2014 at 14:04 EDT

Latest CD4 Stories

6d4febf7b1797690e38c8f5295d01742
2010-07-09 10:53:44

Discovery to advance HIV vaccine design, antibody therapy for other diseases Scientists have discovered two potent human antibodies that can stop more than 90 percent of known global HIV strains from infecting human cells in the laboratory, and have demonstrated how one of these disease-fighting proteins accomplishes this feat. According to the scientists, these antibodies could be used to design improved HIV vaccines, or could be further developed to prevent or treat HIV infection. Moreover,...

2010-07-06 06:00:00

RICHMOND, Calif., July 6 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the publication of data demonstrating the preclinical efficacy of a human stem cell therapy for human immunodeficiency virus (HIV) based on its proprietary zinc finger DNA-binding protein nuclease (ZFN) technology. The ZFN approach enables the permanent disruption of the CCR5 gene, which encodes an important receptor for HIV infection, in all the cell types comprising the immune system...

2010-05-14 12:52:12

HIV disease tends to progress at a faster rate in infected individuals who consume two or more alcoholic drinks a day, according to an important new paper in AIDS Research and Human Retroviruses, a peer-reviewed journal published by Mary Ann Liebert, Inc. The article is available free online. The article, entitled "Alcohol Use Accelerates HIV Disease Progression," clearly demonstrates that frequent alcohol use, defined as two or more drinks daily, is associated with declining CD4+ cell counts...

2010-05-06 10:00:00

MELBOURNE, Australia, May 6 /PRNewswire/ -- The use of rapid point-of-care diagnostic tests for the measurement of CD4 T-cells, a marker of the immune system will be an important factor in improving the lives of people living with HIV and AIDS especially in developing and resource-poor countries. Speaking on global diagnostics at the Bio2010 International Convention in Chicago, Burnet Institute's Associate Professor David Anderson said point-of-care tests that are cheap, easy to use and...

2010-04-29 13:21:45

Limited success in modeling the behavior of the complex, unusual and unpredictable HIV virus has slowed efforts to develop an effective vaccine to prevent AIDS. A new improved modeling system, developed by Chinese researchers, which attempts to incorporate more of the virus' random behavioral dynamics, suggests that a particular type of T cell could be useful in the development of an AIDS vaccine. New research published today, Thursday 29 April, in New Journal of Physics (co-owned by the...

2010-04-27 02:01:00

MELBOURNE, Australia, April 27 /PRNewswire/ -- Scientists at Australia's Burnet Institute have developed a rapid point-of-care diagnostic test for the measurement of CD4 T-cells, a marker of the immune system for people living with HIV and AIDS. Based on the measurement of cell-associated CD4 protein in whole blood samples such as a finger prick, the kit will enable patients to receive appropriate treatment earlier without having to wait for reference laboratory test results which...

9e1d013de4a9c0193aef650dfbf1cf69
2010-04-03 09:29:51

Finding looks at clade C gp120; also reveals unusual autoreactivity between 21c antibody and CD4 receptor Scientists from the California Institute of Technology (Caltech) have provided the first-ever glimpse of the structure of a key protein"”gp120"”found on the surface of a specific subgroup of the human immunodeficiency virus, HIV-1. In addition, they demonstrated that a particular antibody to gp120 makes contact not only with the protein, but with the CD4 receptor that gp120...

2010-03-08 09:39:23

New study from Universite de Montreal and VGTI may lead to improved defenses New findings from a Universit© de Montr©al and the Vaccine and Gene Therapy Institute of Florida (VGTI) study, in collaboration with scientists from the NIH and the McGill University Health Center, may soon lead to an expansion of the drug arsenal used to fight HIV. The Canada-U.S. study published today in the journal Nature Medicine characterizes the pivotal role of two molecules, PD-1 and IL-10, in...

2010-01-19 07:00:00

RICHMOND, Calif., Jan. 19 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented on Friday, January 15, 2010 at the Keystone Symposium Session "HIV Biology and Pathogenesis." Sangamo's collaborator, Carl June, M.D., Director of Translational Research at the Abramson...

2009-11-30 15:34:55

A major obstacle to HIV research is the virus's exquisite specialization for its human host "“ meaning that scientists' traditional tools, like the humble lab mouse, can deliver only limited information. Now, a team of researchers writing in BioMed Central's open access Journal of Biology have made an ingenious assault on this problem by creating a mouse that has key features of HIV infection without being infected with HIV. George Kassiotis, from the Division of Immunoregulation at MRC...